REG - GlobalData PLC - Acquisition of Deallus

GlobalDataAnnouncement

07/01/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250107:nRSG3159Sa&default-theme=true

RNS Number : 3159S  GlobalData PLC  07 January 2025

7 January 2025

 

 

GlobalData Plc

 

Acquisition Updates

 

Healthcare Division: Acquisition of Deallus

 

 

GlobalData Plc ('GlobalData' or the 'Group'), a leading data, analytics, and
insights platform, today announces further progress in its M&A strategy.

 

The Group announces that it has completed the acquisition of Deallus, a
market-leading competitive intelligence solutions provider focused on the
global life sciences sector.

 

During its 20 years in business, Deallus has built deep sector expertise
through supporting clients in key therapy areas, including Oncology,
Neuroscience, Vaccines, Rare Diseases, Cell & Gene, and Immunology. The
combination creates the opportunity for the Group to build deeper, more
embedded relationships with major brands within the pharmaceutical sector and
creates the potential for GlobalData to deliver more value to our clients.

 

The transaction was funded by the Group's new recently announced debt
facilities and completed on 31 December 2024. This represents the fourth
acquisition completed in H2 2024, in addition to the acquisitions of Business
Trade Media International, LinkUp and Celent, which also completed on 31
December 2024 following the satisfaction of certain closing conditions.

 

The Group will issue an update on its trading and FY24 results on 14 January
2025 and will provide further detail on the positive impact of its recent
M&A activity.

 

Mike Danson, CEO of GlobalData PLC, commented: "This acquisition further
enhances our capabilities in delivering life sciences solutions, allowing us
to deliver even more comprehensive insights and services to our clients.
Deallus's deep sector expertise and client-first mindset perfectly align with
our mission to empower decision-makers in navigating the complexities of the
healthcare landscape. Together, we are poised to drive remarkable growth and
deliver exceptional value to our stakeholders."

 

ENQUIRIES

 GlobalData Plc
 Mike Danson, Chief Executive Officer        0207 936 6400
 Graham Lilley, Chief Financial Officer

 J.P. Morgan Cazenove (Nomad, Joint Broker)  0203 493 8000
 Bill Hutchings
 Mose Adigun

 Panmure Liberum (Joint Broker)              0203 100 2000
 Rupert Dearden
 Dougie McLeod

 Investec Bank plc (Joint Broker)            0207 597 5970

 Henry Reast

 Virginia Bull

 FTI Consulting (Financial PR)               0203 727 1000
 Edward Bridges                              globaldata@fticonsulting.com
 Dwight Burden
 Emma Hall

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ACQDGGDBUSGDGUL